Synergistic effects of GS-1101 and Doxorubicin in acute lymphoblastic leukemia cell line - Journal of Mazandaran University of Medical Sciences
Volume 27, Number 153 (10-2017)                   J Mazandaran Univ Med Sci 2017, 27(153): 28-38 | Back to browse issues page


XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Safaroghli-Azar A, Sadreazami P, Bahmani F, Bashash D. Synergistic effects of GS-1101 and Doxorubicin in acute lymphoblastic leukemia cell line. J Mazandaran Univ Med Sci. 2017; 27 (153) :28-38
URL: http://jmums.mazums.ac.ir/article-1-9337-en.html

Abstract:   (155 Views)
Background and purpose: Interest into targeting PI3K in cancer has increased by the recent disclosure that aberrant activity of PI3K/Akt signaling pathway is associated with disease recurrence and poor outcome in different malignancies. The aim of this study was to investigate the potentiating effect of PI3K inhibitor, GS-1101 on doxorubicin-induced cell death in acute lymphoblastic leukemia-derived, Nalm-6 cells.
Materials and methods: In this experimental study, to evaluate whether abrogating PI3K/Akt pathway using GS-1101 could enhance cytotoxic effect of doxorubicin in acute lymphoblastic leukemia, Nalm-6 pre-B ALL cells were subjected to combination treatment and subsequent cell viability. Then cell count, metabolic activity, and transcriptional alteration of apoptosis-related target genes were investigated using Trypan blue exlussion, MTT and Rq-PCR analysis, respectively.
Results: Our data delineated that GS-1101 augments doxorubicin-induced cytotoxic and its anti-proliferative effect, as evidenced by the decreased cell survival, cellular metabolic activity, and reduction in the number of inhibitor-treated viable cells. Moreover, real-time PCR analysis revealed that induction of cell death by the drug combination was associated with increased Bax transcriptional activity (P≤0.01) followed by the elevated molecular ratio of Bax/Bcl-2 (P≤0.001).
Conclusion: This study suggested that abrogation of the PI3K pathway using GS-1101 could potentiate doxorubicin-induced anti-leukemic activity.
 
Full-Text [PDF 1464 kb]   (59 Downloads)    
Type of Study: Research(Original) | Subject: Hematology and Oncology

Add your comments about this article : Your username or email:
Write the security code in the box

Send email to the article author


© 2015 All Rights Reserved | Journal of Mazandaran University of Medical Sciences

Designed & Developed by : Yektaweb